Delayed FDA Studies Raise Safety Concerns

The FDA has faced significant delays in mandated postmarket safety studies for drugs like Tavneos, leaving questions about drug safety unresolved while patients continue treatment. Recent FDA policy to require fewer pre-approval clinical trials increases reliance on these delayed postmarket studies, raising concerns about patient risk and healthcare costs.

This Wire brief sits within Fusion42's coverage of Health.